| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/KI.2015.322 |
| P8608 | Fatcat ID | release_l5vmrwlecfbs3iewpoe22p6lpe |
| P698 | PubMed publication ID | 26759049 |
| P50 | author | Jonathan Barratt | Q37385409 |
| Daniel C. Cattran | Q116025556 | ||
| Heather N. Reich | Q116025592 | ||
| P2093 | author name string | Rosanna Coppo | |
| Andrew M Herzenberg | |||
| John Feehally | |||
| Ian S D Roberts | |||
| Sean J Barbour | |||
| Gabriela Espino-Hernandez | |||
| OXFORD DERIVATION AND NORTH AMERICAN VALIDATION | |||
| Oxford Derivation North American Validation and VALIGA Consortia | |||
| Oxford Derivation, North American Validation and VALIGA Consortia | |||
| VALIGA | |||
| P2860 | cites work | Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond | Q29614697 |
| A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group | Q29614889 | ||
| Histopathologic features aid in predicting risk for progression of IgA nephropathy | Q33684014 | ||
| Predicting progression in IgA nephropathy | Q34092948 | ||
| Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments | Q34284540 | ||
| Evaluation of the Oxford Classification of IgA nephropathy: a systematic review and meta-analysis | Q34355000 | ||
| The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility | Q34658762 | ||
| The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification | Q34658768 | ||
| Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. | Q34658876 | ||
| Predicting the risk for dialysis or death in IgA nephropathy | Q34726899 | ||
| The need for improved uptake of the KDIGO glomerulonephritis guidelines into clinical practice in Canada: a survey of nephrologists | Q35310613 | ||
| Validation study of oxford classification of IgA nephropathy: the significance of extracapillary proliferation | Q35664626 | ||
| Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the oxford classification | Q35983485 | ||
| The use of the Oxford classification of IgA nephropathy to predict renal survival | Q35985818 | ||
| Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study | Q36003136 | ||
| Interpreting incremental value of markers added to risk prediction models | Q36489197 | ||
| Dual effects of RAS blockade on blood pressure and podocyte function | Q37051475 | ||
| Risk stratification for progression of IgA nephropathy using a decision tree induction algorithm | Q37135691 | ||
| A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study | Q37354870 | ||
| Development and validation of a prediction rule using the Oxford classification in IgA nephropathy | Q37359051 | ||
| Risk stratification of patients with IgA nephropathy | Q38002145 | ||
| Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial | Q44449839 | ||
| Several methods to assess improvement in risk prediction models: Extension to survival analysis | Q44667332 | ||
| Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial | Q44705281 | ||
| Long-term hemodynamic and molecular effects persist after discontinued renin-angiotensin system blockade in patients with type 1 diabetes mellitus | Q44792185 | ||
| Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial | Q46310346 | ||
| Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury | Q57703725 | ||
| A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study | Q79844393 | ||
| Remission of proteinuria improves prognosis in IgA nephropathy | Q81542864 | ||
| Validation of the Toronto formula to predict progression in IgA nephropathy | Q81711653 | ||
| Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study | Q83188524 | ||
| Validation of the Oxford classification of IgA nephropathy | Q84039211 | ||
| Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population | Q85030658 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 167-175 | |
| P577 | publication date | 2015-10-28 | |
| 2016-01-01 | |||
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | The MEST score provides earlier risk prediction in IgA nephropathy | |
| The MEST score provides earlier risk prediction in lgA nephropathy | |||
| P478 | volume | 89 |
| Q92524303 | "Associated" or "Secondary" IgA nephropathy? An outcome analysis |
| Q94103592 | 15th International Symposium on IgANephropathy - IIgANN 2018, Buenos Aires, September 27-29, 2018: Summaries |
| Q58113293 | A grading system that predicts the risk of dialysis induction in IgA nephropathy patients based on the combination of the clinical and histological severity |
| Q87717562 | Are we ready for targeted therapy for IgA nephropathy? |
| Q92741684 | Assessment of active tubulointerstitial nephritis in non-scarred renal cortex improves prediction of renal outcomes in patients with IgA nephropathy |
| Q38871090 | Biomarkers and targeted new therapies for IgA nephropathy |
| Q101119837 | CD71 Mesangial IgA1 Receptor and The Progression of IgA Nephropathy |
| Q38999373 | Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients |
| Q51758616 | Clinical usefulness of the Oxford classification in determining immunosuppressive treatment in IgA nephropathy. |
| Q36110820 | Comparison of different normalization strategies for the analysis of glomerular microRNAs in IgA nephropathy |
| Q53556768 | Con: STOP immunosuppression in IgA nephropathy. |
| Q38817381 | Corticosteroids in IgA Nephropathy: Lessons from Recent Studies |
| Q47100563 | Elevated serum fibrinogen level is an independent risk factor for IgA nephropathy |
| Q93069858 | Evaluating a New International Risk-Prediction Tool in IgA Nephropathy |
| Q92513009 | Evolving Clinical Applications of Tissue Transcriptomics in Kidney Disease |
| Q64115492 | Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression |
| Q53278365 | Glomerular disease: Updated Oxford Classification of IgA nephropathy: a new MEST-C score. |
| Q91650815 | Graft failure of IgA nephropathy in renal allografts following living donor transplantation: predictive factor analysis of 102 biopsies |
| Q90461387 | Has The Time Arrived to Refine The Indications of Immunosuppressive Therapy and Prognosis in IgA Nephropathy? |
| Q93044531 | Higher serum galactose-deficient immunoglobulin A1 concentration is associated with stronger mesangial cellular inflammatory response and more severe histologic findings in immunoglobulin A nephropathy |
| Q90451514 | IgA Nephropathy Susceptibility Loci and Disease Progression |
| Q88757326 | IgA Nephropathy in Salvador, Brazil. Clinical and laboratory presentation at diagnosis |
| Q51834649 | IgA Nephropathy. |
| Q57100792 | IgA Nephropathy: A European Perspective in the Corticosteroid Treatment |
| Q49477908 | IgA nephropathy in Greece: data from the registry of the Hellenic Society of Nephrology. |
| Q57071248 | IgA nephropathy in Salvador, Brazil: a more aggressive disease? |
| Q33893355 | Increased C4 and decreased C3 levels are associated with a poor prognosis in patients with immunoglobulin A nephropathy: a retrospective study |
| Q40456075 | Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies. |
| Q39229309 | Is there a role for immunosuppression in immunoglobulin A nephropathy? |
| Q43924057 | Long-term outcome in 145 patients with assumed benign immunoglobulin A nephropathy |
| Q38824816 | Markers for the progression of IgA nephropathy |
| Q91761381 | Maximum Glomerular Diameter and Oxford MEST-C Score in IgA Nephropathy: The Significance of Time-Series Changes in Pseudo-R2 Values in Relation to Renal Outcomes |
| Q92256415 | Minor Glomerular Abnormalities are Associated with Deterioration of Long-Term Kidney Function and Mitochondrial Injury |
| Q51734842 | Moderator's view: Treatment of IgA nephropathy-getting comfortable with uncertainty. |
| Q39839285 | NLRP3 Localizes to the Tubular Epithelium in Human Kidney and Correlates With Outcome in IgA Nephropathy |
| Q91975813 | Random forest can accurately predict the development of end-stage renal disease in immunoglobulin a nephropathy patients |
| Q40168439 | Remission of Hematuria Improves Renal Survival in IgA Nephropathy |
| Q59336609 | Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores) |
| Q39457194 | Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort. |
| Q36243259 | Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case-control study |
| Q36307746 | Significance of clinical and morphological prognostic risk factors in IgA nephropathy: follow-up study of comparison patient groups with and without renoprotection |
| Q89627686 | TESTING Corticosteroids in IgA Nephropathy: A Continuing Challenge |
| Q58734688 | The Emerging Role of Pathogenesis of IgA Nephropathy |
| Q92714448 | The association of the CMIP rs16955379 polymorphism with dyslipidemia and the clinicopathological features of IgA nephropathy |
| Q49874313 | The clinical relevance of plasma CD147/basigin in biopsy-proven kidney diseases |
| Q94606273 | Time series changes in pseudo-R2 values regarding maximum glomerular diameter and the Oxford MEST-C score in patients with IgA nephropathy: A long-term follow-up study |
| Q33683223 | Tubular atrophy/interstitial fibrosis scores of Oxford classification combinded with proteinuria level at biopsy provides earlier risk prediction in lgA nephropathy |
| Q48219502 | Value of the Oxford classification of IgA nephropathy in children with Henoch-Schönlein purpura nephritis. |
| Q87753251 | [Clinical and pathological features in IgA nephropathy with IgG deposition in the glomerular mesangial area] |
| Q89272510 | [Pathophysiology and treatment of IgA nephropathy] |
Search more.